Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading this week, for the November 21st expiration. One of the key inputs that goes into the price an option ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Results from a Phase 3 clinical trial, SARIL-RA-MONARCH, assessing Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi 's ...

View Regeneron Pharmaceuticals, Inc. (REGN) current and estimated P/E ratio data provided by Seeking Alpha.

On March 10, the county legislature approved $6 million for the Pine Hills Land Authority to maintain campus security and infrastructure as revitalization plans unfold.

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Regeneron Pharmaceuticals Inc. closed 45.10% below its 52-week high of $1,211.20, which the company reached on August 27th.

In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better ...

San Francisco, California--(Newsfile Corp. - March 3, 2025) - Biotechnology giant Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is embroiled in a securities class action lawsuit, alleging the ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results ...